Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Tenecteplase per Ictus in Finestra Terapeutica Tardiva Guidato da Discordanza DWI-FLAIR (TRUST-MISMATCH)

5 novembre 2026 aggiornato da: Bo Song, The First Affiliated Hospital of Zhengzhou University

Tenecteplase Trombolisi per Ictus Ischemico Acuto nella Finestra Temporale 4,5-9 Ore Guidata da DWI-FLAIR Mismatch: Uno Studio Multicentrico, Prospettico, Randomizzato, in Doppio Cieco, Controllato con Placebo

The goal of this clinical trial is to evaluate the efficacy and safety of tenecteplase administered 4.5-9 hours after stroke onset (defined as the time the patient was first found with symptoms, including wake-up stroke and unwitnessed stroke) in patients with acute ischemic stroke (AIS) guided by DWI-FLAIR mismatch on MRI. The main questions it aims to answer are:

  1. Does tenecteplase improve functional outcomes at 90 days compared with standard treatments in AIS patients administered 4.5-9 hours after stroke onset guided by DWI-FLAIR mismatch?
  2. The safety of tenecteplase thrombolysis for AIS patients in the 4.5-9 hours guided by DWI-FLAIR mismatch.

Researchers will compare tenecteplase to placebo to see if it is effective and safe for these patients.

Participants will be randomly assigned (1:1) immediately after randomization:

  • Tenecteplase group: received tenecteplase, intravenously as a bolus administered over a period of 5 to 10 seconds at a dose of 0.25 mg per kilogram (maximum dose, 25 mg), plus aspirin placebo (300 mg).
  • Control group: aspirin (300 mg) plus tenecteplase placebo. From day 2 to day 90, all patients will be conformed to the 2023 Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke.

Panoramica dello studio

Descrizione dettagliata

Current clinical guidelines recommend intravenous thrombolysis (IVT) for eligible AIS patients within 4.5 hours of symptom onset. However, approximately 67 to 75% of patients present after 4.5 hours after stroke onset or with an unknown time of onset. CT perfusion (CTP) and perfusion-diffusion magnetic resonance imaging (MRI) have demonstrated that potentially viable brain tissue may persist beyond 4.5 hours after stroke onset. Recent trials, such as EXTEND, TRACE III, and the HOPE study, suggest that IVT can improve functional outcomes in AIS patients with salvageable brain tissue identified beyond 4.5 hours and up to 24 hours, using advanced perfusion imaging. Nonetheless, due to the high cost of perfusion software in developing countries, extended-window thrombolysis has not been widely implemented in many stroke centers. Therefore, it is crucial to develop alternative strategies to guide IVT in patients beyond 4.5 hours.

In recent years, the mismatch between a visible acute ischemic lesion on diffusion-weighted imaging (DWI) and the absence of a corresponding hyperintensity on fluid-attenuated inversion recovery (FLAIR) has been recognized as a predictor of symptom onset within 4.5 hours before imaging. The WAKE-UP trial demonstrated that among AIS patients with unknown time of onset (last known well >4.5 hours) and DWI-FLAIR mismatch, IVT administered within 4.5 hours after symptom recognition significantly improved functional outcomes. However, approximately 30% of AIS patients exhibit DWI-FLAIR mismatch between 4.5 and 9 hours after onset. Whether these patients can benefit from thrombolysis remains uncertain.

TRUST-MISMATCH is a multicenter, prospective, randomized, double-blind, placebo-controlled clinical. We want to evaluate the efficacy and safety of tenecteplase administered 4.5-9 hours after stroke onset (defined as the time the patient was first found with symptoms, including wake-up stroke and unwitnessed stroke) in AIS patients guided by DWI-FLAIR mismatch on MRI.

Tipo di studio

Interventistico

Iscrizione (Stimato)

564

Fase

  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • Henan
      • Zhengzhou, Henan, Cina, 450052
        • Reclutamento
        • The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Age ≥ 18 years;

  2. AIS with symptom onset 4.5-9 hours before enrollment, including wake-up stroke and unwitnessed stroke (onset time defined as when symptoms were first noticed);

  3. Imaging criteria:

    1. DWI-FLAIR mismatch: visible lesion on DWI with no marked visible lesion on FLAIR;
    2. DWI infarct core not exceeding one-third of the middle cerebral artery territory, one-half of the anterior cerebral artery territory, or one-half of the posterior cerebral artery territory;
  4. NIHSS score 4-25;

  5. First-ever stroke or previous stroke without significant disability (pre-stroke mRS ≤ 1);

  6. Signed informed consent from the patient or legally authorized representative.

Exclusion Criteria:

  1. Planned endovascular treatment;
  2. Contradictory to MRI examination;
  3. MRI image not qualified for evaluation;
  4. Obvious head injuries or strokes within 3 months;
  5. Subarachnoid or intracranial hemorrhage;
  6. History of intracranial hemorrhage;
  7. Intracranial tumor, arteriovenous malformation or aneurysm;
  8. Intracranial or spinal cord surgery within 3 months;
  9. Active internal hemorrhage;
  10. platelet count of <100000/mm3;
  11. Aortic arch dissection;
  12. Heparin therapy within 24 hours;
  13. Oral warfarin is being taken and INR>1.6 or APTT abnormal;
  14. Oral anticoagulation therapy;
  15. Systolic pressure≥185 mmHg or diastolic pressure≥110 mmHg;
  16. Blood glucose < 50 mg/dl (2.7mmol/L);
  17. Pregnancy;
  18. Neurological deficit after epileptic seizures;
  19. Major surgery within 1 month;
  20. Gastrointestinal or urinary tract hemorrhage within the previous 30 days;
  21. Myocardial infarction within 3 months;
  22. Allergy to study drugs;
  23. Unlikely to adhere to the trial protocol or follow-up;
  24. Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study;
  25. Participation in other interventional clinical trials within the previous 3 months.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Quadruplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Tenecteplase group:

Patients will receive tenecteplase, intravenously as a bolus administered over a period of 5 to 10 seconds at a dose of 0.25 mg per kilogram (maximum dose, 25 mg), plus aspirin placebo (300 mg) immediately after randomization.From day 2 to day 90, all patients will be conformed to the 2023 Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke.

TNK-tPA (0.25 mg/kg, to maximum of 25mg)

Asprin (placebo)

TNK-tPA (placebo)

Comparatore attivo: Control group

Patients will receive asprin(300mg) plus intravenous TNK(placebo, 0.25mg/kg, a maximum of 25 mg) immediately after randomization. From day 2 to day 90, patients will be conformed to the 2023 Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke.

Asprin (placebo)

TNK-tPA (placebo)

Asprin (300mg)

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Modified Rankin Scale (mRS)
Lasso di tempo: 90 ± 7 days

Proportion of subjects of excellent outcome defined as mRS (0-1) at 90 ± 7 days.

90 ± 7 days

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Modified Rankin Scale (mRS)
Lasso di tempo: 90 ± 7 days

Proportion of subjects of excellent outcome defined as mRS (0-2) at 90 ± 7 days.

90 ± 7 days
Modified Rankin Scale (mRS)
Lasso di tempo: 90 days

Ordinal shift analysis of mRS at 90 days

90 days
National Institutes of Health Stroke Scale (NIHSS)
Lasso di tempo: 72 hours and 7 ± 1 days (or at discharge)

Proportion of subjects with an improvement in NIHSS score of ≥2 points from baseline.

72 hours and 7 ± 1 days (or at discharge)
National Institutes of Health Stroke Scale (NIHSS)
Lasso di tempo: 72 hours and 7 ± 1 days (or at discharge)

Proportion of subjects achieving an NIHSS score of ≤1.

72 hours and 7 ± 1 days (or at discharge)
Barthel (BI)
Lasso di tempo: 90 ± 7 days

Barthel Index score at 90 ± 7 days.

90 ± 7 days
EuroQol 5-Dimension (EQ-5D)
Lasso di tempo: 90 ± 7 days

Quality of life measured by EQ-5D scale at 90 ± 7 days.

90 ± 7 days
Modified Rankin Scale (mRS)
Lasso di tempo: 90 ± 7 days
  1. Proportion of subjects of excellent outcome defined as mRS (0-2) at 90 ± 7 days.
  2. Ordinal distribution of mRS at 90 ± 7 days
90 ± 7 days

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Symptomatic intracranial hemorrhage (sICH)
Lasso di tempo: 36 hours

Proportion of subjects with symptomatic intracranial hemorrhage (sICH) within 36 hours (according to the ECASS III criteria for the primary safety analysis, with SITS-MOST and Heidelberg definitions used for supportive analyses).

36 hours
Death
Lasso di tempo: 90 days

Overall mortality rate at 90 days.

90 days
Systemic bleeding
Lasso di tempo: 90 days

Systemic bleeding at 90 days (according to the GUSTO criteria)

90 days
Adverse events (AEs)/ serious adverse events (SAEs)
Lasso di tempo: 90 ± 7 days

Proportion of patients with adverse events (AEs)/ serious adverse events (SAEs) within 90 ± 7 days.

90 ± 7 days
Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)
Lasso di tempo: 90 ± 7 days

Proportion of subjects experiencing MACCE (defined as ischemic stroke, hemorrhagic stroke, transient ischemic attack, myocardial infarction, or vascular death).

90 ± 7 days

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Cattedra di studio: Bo Song, MD, Department of Neurology, the First Affiliated Hospital of Zhengzhou University

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

2 novembre 2026

Completamento primario (Stimato)

29 febbraio 2028

Completamento dello studio (Stimato)

31 ottobre 2028

Date di iscrizione allo studio

Primo inviato

6 aprile 2026

Primo inviato che soddisfa i criteri di controllo qualità

17 aprile 2026

Primo Inserito (Effettivo)

20 aprile 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

9 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

5 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

prodotto fabbricato ed esportato dagli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi